Examination of the expression of PD-L1 in the tumor and in the stroma at the tumor periphery and CD8 (to detect this tumor-infiltrating lymphocyte subset) in this cohort by IHC (Fig. 3a, b) revealed that more than 50% of GC cases expressed PD-L1 in cancer and/or in infiltrating immune cells (Table 2). The gene discussed is CD8A; the disease is neoplasm.